Icatibant Teva (Icatibant Acetate)

Icatibant acetate works as a competitive antagonist at the bradykinin B2 receptor on blood‑vessel walls. By preventing bradykinin from binding, it stops the cascade that leads to vasodilation and increased vascular permeability, thereby limiting the swelling that characterises HAE attacks.

The dose of Icatibant Teva is determined by the prescribing clinician. It is administered as a subcutaneous injection, and the exact amount, frequency and timing are individualized based on the severity of the attack and the patient’s clinical response.

Safety data for icatibant acetate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and any required import documentation.

The main alternative to icatibant is plasma‑derived or recombinant C1‑inhibitor concentrate, which replaces the missing protein. Icatibant directly blocks bradykinin receptors, offering a rapid, self‑administered subcutaneous option, whereas C1‑inhibitor products are given intravenously and act by restoring the deficient inhibitor.

Icatibant Teva should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

The medication is given as a single subcutaneous injection into the abdomen or thigh. Patients or caregivers should clean the injection site with an alcohol swab, use a sterile needle, inject the prescribed volume, and then safely dispose of the needle in an approved sharps container.

Serious adverse events include anaphylaxis, severe hypotension, and airway‑related angioedema that can be life‑threatening. Patients should be monitored for signs of allergic reaction, sudden drop in blood pressure, or swelling of the face, lips or throat, and seek immediate medical attention if these occur.

Icatibant Teva is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of its excipients. Caution is also advised for patients with a history of severe allergic reactions, uncontrolled cardiovascular disease, or those taking medications that significantly increase bradykinin levels.